IN THE SPOTLIGHT (Paris/Healthtech/Investment) - Lauxera Capital Partners closes its Lauxera Growth II fund at €520M, exceeding its initial target of €500M and doubling the size of its first vehicle. This growth equity fund targets 12 to 15 investmen

WORLD (United States/Pharma partnerships/R&D) – Parabilis Medicines forges a strategic collaboration with Regeneron around its Helicon™ peptide platform, a new class of stabilized alpha‑helical peptides capable of penetrating cells and targeting intr

WORLD(Australia/Medtech/Urology) - NinaMED launches with $13.75M in financing led by SPRIM Global Investments to develop and commercialize the NiNA System, a non‑invasive, at‑home, drug‑free neuromodulation device for overactive bladder (OAB), under

MONDE(United States/Medtech/Urology) - Rivermark Medical closes a $20M Series D round led by Andera Partners, with support from existing investors and a strategic investor (not disclosed), to accelerate development of its FloStent system for benign p

WORLD(United States/Healthtech/Preventive medicine) - PeterMD is opening its share capital to a majority takeover by the Lorient health fund (alongside Emanate) to accelerate the national deployment of its "Medicine 3.0" platform, a market estimated

(Rouen/Medtech/Cardiology) - Robocath has completed recruitment for its first “first‑in‑human” study on its next‑generation robotic platform for coronary angioplasty, conducted on 20 patients at the Centre Cardiologique du Nord (Saint‑Denis) with les

WORLD(United States/Biotech/Oncology) - Cartography Biosciences receives an undisclosed strategic investment from the Samsung Life Science Fund to support its ATLAS/SUMMIT antigen discovery platform and antibody pipeline, including the T-cell engager

WORLD(United States/Biotech/Microbiome & IO) - Kanvas Biosciences closes a $48M Series A co‑led by DCVC and Lions Capital, followed by the Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund and Pangaea Ventures. This round brings total funding to $78M

EUROPE(United Kingdom/Biotech/Oncology) - Cytospire Therapeutics closes an oversubscribed Series A of £61M ($83M) led by 4BIO Capital followed by Servier Ventures (first deal from its corporate fund), British Business Bank, Sound Bioventures, Criteri

WORLD(United States/Biotech/CNS gene therapy) - Latus Bio closes a $97M Series A, including a $43M extension led by 8VC, with support from existing investors (DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, Hatc

WORLD(China/Biotech/CAR-T cell therapy) - Vivacta Biotechnology closes two tranches of Series A and A+ financing totaling over $50M, led by Loyal Valley Capital and Decheng Capital, with participation from OrbiMed and Eisai Innovation. The transactio

MONDE(United States/Pharma/Women's Health) - Organon signs a deal to be acquired by Sun Pharmaceutical Industries for $11.75 billion, or $14 per share in cash. The transaction values the company at a 103% premium and is expected to close in early 202